Conference Coverage
Conference Coverage
Advertisement
Rob DillardASCO 2023 | June 3, 2023
Pelabresib monotherapy appears to be clinically beneficial in patients who have high-risk essential thrombocythemia.
Read More
Rob DillardASCO 2023 | June 3, 2023
Ruxolitinib is effective at controlling hematocrit in the majority of patients with polycythemia vera.
Rob DillardASCO 2023 | June 3, 2023
The up-regulation of glutaminase is a common feature in Philadelphia-negative and JAK2-V617F-driven MPNs.
Rob DillardASCO 2023 | June 3, 2023
Zilurgisertib appears safe and well tolerated in patients who have anemia due to myelofibrosis.
Rob DillardASCO 2023 | June 2, 2023
A proof-of-concept study indicates the combined use of ruxolitinib and magrolimab is effective in treating myelofibrosis.
Rob DillardASCO 2023 | June 2, 2023
The treatment combination of selinexor plus ruxolitinib is effective in treatment-naïve patients with myelofibrosis.
Rob DillardASCO 2023 | June 2, 2023
The JAK inhibitor momelotinib appears to have a superior safety profile compared with fedratinib in myelofibrosis.
Rob DillardASCO 2023 | June 2, 2023
Patients with myelofibrosis with a certain platelet count who achieve spleen volume reduction on pacritinib have better OS.
Rob DillardASCO 2023 | May 31, 2023
US veterans who were exposed to Agent Orange have an increased risk of myeloproliferative neoplasms.
Rob DillardASCO 2023 | May 31, 2023
The novel JAK1-sparing inhibitor pacritinib is effective at reducing spleen enlargement and disease burden in MF patients.
Rob DillardASCO 2023 | May 31, 2023
The safety and efficacy of luspatercept is favorable for treating anemia in patients with myelofibrosis.
Rob DillardASCO 2023 | May 31, 2023
Patients admitted for atrial fibrillation who have myeloproliferative neoplasms have an increased risk of bleeding.
Rob DillardASCO 2023 | May 26, 2023
Extending colorectal cancer screening to older populations using stool testing results in more life years gained.
Rob DillardASCO 2023 | May 25, 2023
People with a history of skin cancer lack sufficient knowledge on photoprotection, study finds.
Rob DillardSCAI 2023 Scientific Sessions | May 22, 2023
Ticagrelor monotherapy is linked with similar rates of recurrent coronary revascularization compared with standard therapy.
Rob DillardSCAI 2023 Scientific Sessions | May 19, 2023
Dr. George D. Dangas, about a study he led which analyzed the predictive value of the thrombotic risk criteria.
Rob DillardSCAI 2023 Scientific Sessions | May 19, 2023
Dr. Tanvir K. Bajwa talks about the FX TAVR system, designed to improve ease of use in coronary access.
Rob DillardSCAI 2023 Scientific Sessions | May 19, 2023
Pulmonary embolism patients treated with mechanical thrombectomy have improved outcomes and quality of life.
Rob DillardSCAI 2023 Scientific Sessions | May 18, 2023
Marijuana users incur more than three times the risk of developing peripheral artery disease.
Rob DillardSCAI 2023 Scientific Sessions | May 18, 2023
The novel Supira 10F system is a safe and effective percutaneous ventricular assist device for high-risk PCI.
Advertisement
Advertisement
Advertisement
Latest News

June 3, 2023